A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer

European Journal of Cancer

Volumn 50, Issue 16, 2014, Pages 2866-2876

  Fan, Ping ^a   Agboke, Fadeke A ^a   Cunliffe, Heather E ^b,c   Ramos, Pilar ^b   Jordan, V Craig ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Focal adhesion molecules; Insulin like growth factor 1 receptor beta (IGF 1R ); Non genomic pathway; Resistance; Selective oestrogen receptor modulator (SERM)

Indexed keywords

AFIMOXIFENE; BAZEDOXIFENE; ENDOXIFEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; FOCAL ADHESION KINASE; FULVESTRANT; INSULIN LIKE GROWTH FACTOR 1 RECEPTOR BETA; MESSENGER RNA; PROTEIN PS2; RALOXIFENE; RECEPTOR; STEROID RECEPTOR COACTIVATOR 3; UNCLASSIFIED DRUG; ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN C RECEPTOR; TAMOXIFEN;

ARTICLE; BREAST CANCER; CELL ACTIVATION; CELL GROWTH; CELL STIMULATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ESTROGEN RESPONSIVE ELEMENT; FOCAL ADHESION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; MCF 7 CELL LINE; MOLECULAR MODEL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WILD TYPE; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; FEMALE; HUMANS; MCF-7 CELLS; PHOSPHORYLATION; RECEPTOR, IGF TYPE 1; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 84923200015     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.08.011     Document Type: Article

References (47)

1. V.C. Jordan Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer Endocr Relat Cancer 21 2014 R235 R246
2. C. Davies, J. Godwin, and R. Gray Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet 378 2011 771 784
3. C. Davies, H. Pan, and J. Godwin Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Lancet 381 2013 805 816
4. M. Dowsett, J. Cuzick, and J. Ingle Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen J Clin Oncol 28 2010 509 518
5. P.E. Goss, J.N. Ingle, and S. Martino Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17 J Clin Oncol 25 2007 2006 2011
6. M.M. Gottardis, and V.C. Jordan Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration Cancer Res 48 1988 5183 5187
7. M.M. Gottardis, R.J. Wagner, E.C. Borden, and V.C. Jordan Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro Cancer Res 49 1989 4765 4769
8. K. Yao, E.S. Lee, and D.J. Bentrem Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice Clin Cancer Res 6 2000 2028 2036
9. V.C. Jordan The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer-survival or death? J Clin Oncol 26 2008 3073 3082
10. E.A. Ariazi, H.E. Cunliffe, and J.S. Lewis-Wambi Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time Proc Natl Acad Sci USA 108 2011 18879 18886
11. J.N. Ingle, D.J. Ahmann, and S.J. Green Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer N Engl J Med 304 1981 16 21
12. C.K. Osborne, J. Pippen, and S.E. Jones Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial J Clin Oncol 20 2002 3386 3395
13. A. Howell, J.F. Robertson, and J. Quaresma Albano Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment J Clin Oncol 20 2002 3396 3403
14. J.S. Lewis, K. Meeke, and C. Osipo Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation J Natl Cancer Inst 97 2005 1746 1759
15. R.X. Song, G. Mor, and F. Naftolin Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol J Natl Cancer Inst 93 2001 1714 1723
16. M.J. Ellis, F. Gao, and F. Dehdashti Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study JAMA 302 2009 774 780
17. G.L. Anderson, R.T. Chlebowski, and A.K. Aragaki Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial Lancet Oncol 13 2012 476 486
18. P. Fan, O.L. Griffith, and F.A. Agboke c-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells Cancer Res 73 2013 4510 4520
19. P. Fan, F.A. Agboke, and R.E. McDaniel Inhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells Eur J Cancer 50 2014 457 468
20. P. Fan, and V.C. Jordan Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations Steroids 2014 [Epub ahead of print]
21. S. Sengupta, I. Obiorah, P.Y. Maximov, R. Curpan, and V.C. Jordan Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells Br J Pharmacol 169 2013 167 178
22. J.S. Lewis-Wambi, H. Kim, R. Curpan, R. Grigg, M.A. Sarker, and V.C. Jordan The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1 Mol Pharmacol 80 2011 610 620
23. M.D. Johnson, H. Zuo, and K.H. Lee Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen Breast Cancer Res Treat 85 2004 151 159
24. J.I. Schafer, H. Liu, D.A. Tonetti, and V.C. Jordan The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor Cancer Res 59 1999 4308 4313
25. R. Schiff, P. Reddy, and M. Ahotupa Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo J Natl Cancer Inst 92 2000 1926 1934
26. Y. Shang, and M. Brown Molecular determinants for the tissue specificity of SERMs Science 295 2002 2465 2468
27. P. Labhart, S. Karmakar, and E.M. Salicru Identification of target genes in breast cancer cells directly regulated by the SRC-3/AIB1 coactivator Proc Natl Acad Sci USA 102 2005 1339 1344
28. R.X. Song, C.J. Barnes, Z. Zhang, Y. Bao, R. Kumar, and R.J. Santen The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane Proc Natl Acad Sci USA 101 2004 2076 2081
29. P. Fan, J. Wang, R.J. Santen, and W. Yue Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells Cancer Res 67 2007 1352 1360
30. S. Hiscox, N.J. Jordan, and C. Smith Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells Breast Cancer Res Treat 115 2009 57 67
31. Y. Zhao, and M.D. Planas-Silva Mislocalization of cell-cell adhesion complexes in tamoxifen-resistant breast cancer cells with elevated c-Src tyrosine kinase activity Cancer Lett 275 2009 204 212
32. P. Fan, R.E. McDaniel, H.R. Kim, D. Clagett, B. Haddad, and V.C. Jordan Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines Eur J Cancer 48 2012 3488 3498
33. M.M. Gottardis, S.Y. Jiang, M.H. Jeng, and V.C. Jordan Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens Cancer Res 49 1989 4090 4093
34. E.S. Lee, J.M. Schafer, and K. Yao Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice Clin Cancer Res 6 2000 4893 4899
35. S.E. Wardell, E.R. Nelson, C.A. Chao, and D.P. McDonnell Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease Clin Cancer Res 19 2013 2420 2431
36. C. Osipo, K. Meeke, and D. Cheng Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer Int J Oncol 30 2007 509 520
37. I.R. Hutcheson, J.M. Knowlden, and T.A. Madden Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells Breast Cancer Res Treat 81 2003 81 93
38. R.B. Riggins, K.S. Thomas, and H.Q. Ta Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b Cancer Res 66 2006 7007 7015
39. S. Massarweh, C.K. Osborne, and C.J. Creighton Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function Cancer Res 68 2008 826 833
40. J.M. Knowlden, I.R. Hutcheson, D. Barrow, J.M. Gee, and R.I. Nicholson Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor Endocrinology 146 2005 4609 4618
41. D.H. Fagan, R.R. Uselman, D. Sachdev, and D. Yee Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment Cancer Res 72 2012 3372 3380
42. A.V. Lee, J.G. Jackson, and J.L. Gooch Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo Mol Endocrinol 13 1999 787 796
43. M.A. Becker, Y.H. Ibrahim, X. Cui, A.V. Lee, and D. Yee The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells Mol Endocrinol 25 2011 516 528
44. S.C. Drury, S. Detre, and A. Leary Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment Endocr Relat Cancer 18 2011 565 577
45. D.H. Shin, H.J. Lee, and H.Y. Min Combating resistance to anti-IGFR antibody by targeting the integrin β3-Src pathway J Natl Cancer Inst 105 2013 1558 1570
46. E.E. Sweeney, R.E. McDaniel, P.Y. Maximov, P. Fan, and V.C. Jordan Models and mechanisms of acquired antihormone resistance in breast cancer: significant clinical progress despite limitations Horm Mol Biol Clin Investig 9 2012 143 163
47. A.S. Levenson, and V.C. Jordan MCF-7: the first hormone-responsive breast cancer cell line Cancer Res 57 1997 3071 3078